In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
Two of Madonna’s Blond Ambition dancers are long-term survivors now shining the spotlight on HIV.
Celebrating 20 years of effective HIV treatment
“We need drugs that are gentler, kinder, better and cheaper.”
There are approximately 36.9 million people living with HIV worldwide
A new novel explores the early years of the AIDS epidemic and imagines what lies in the future.
Here’s a timeline of the highlights.
This quick-reference chart compares available medication options for HIV.
I admit to being a longtime Madonna fan.
Feedback on the issue of gay men’s attraction to crystal meth and Bernie Sanders’s AIDS plan.
The International AIDS Vaccine Initiative (IAVI) marks 20 years in the search for an end to the epidemic.
Doug Meyer makes sculptures of creative icons lost to AIDS.
This free online program helps HIV-positive smokers kick the habit.
The documentary Desert Migration spotlights 13 long-term survivors, all men, now living in Palm Springs, California.
The painter Hugh Steers died of AIDS-related illness at age 32 in 1995, a time when figurative painting like his was not in vogue.
Daniel Szymczyk, founder and CEO of The HIV League, shares why he started the nonprofit group and how running became a passion.
POZ recently asked whether you’ve ever participated in a clinical trial or would consider it. Here are your responses.
Sending fewer men to prison and reducing sentences for those who are incarcerated could slow the spread of HIV.
Gilead Sciences’ HCV combo tablet regimen of Sovaldi and velpatasvir can be combined safely with most “boosted” antiretroviral treatment...
An HIV cure drug from Gilead Sciences, GS-9620, has shown promise in rhesus macaque monkeys.
People contracting HIV are increasingly acquiring strains that are resistant to antiretrovirals (ARVs).
A new study suggests the HIV epidemic is actually in much better shape.
A slew of media outlets erroneously reported that scientists might be just three years away from developing a cure for HIV.
The U.S. Food and Drug Administration approved Gilead Sciences’ Descovy for the treatment of HIV in combination with other antiretrovirals.
Beginning antiretroviral treatment for HIV may provide a boost to liver health among those with and without hepatitis B or C viruses.
Starting HIV treatment soon after diagnosis leads to modest improvements in quality of life compared with delaying treatment.
Gregg Gonsalves first became involved in AIDS activism in the late 1980s, working with ACT UP Boston before moving to New York City.